# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Semnur Pharmaceuticals, a subsidiary of Scilex, plans a business combination with Denali Capital Acquisition Corp. Semnur's...
Scilex is expected to be the majority holder of the combined company following completion of the proposed business combination.
June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...
- SEC Filing
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Scilex Holding (NASDAQ:SCLX) with a Buy and maintains $7 price...
The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and resea...